Literature DB >> 8873596

DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata.

Y Pommier1, G Kohlhagen, C Bailly, M Waring, A Mazumder, K W Kohn.   

Abstract

Ecteinascidin 743 is one of several related marine alkaloids isolated from the Caribbean tunicate Ecteinascidia turbinata. It is remarkably active and potent in a variety of in vitro and in vivo systems and has been selected for development as an anticancer agent. The present study investigates the interactions of ecteinascidin 743 with DNA. Ecteinascidin 743 retarded the electrophoretic migration of both supercoiled and relaxed simian virus 40 DNA even in the presence of sodium dodecyl sulfate and after ethanol precipitation, consistent with covalent DNA modifications. Similar results were obtained in a DNA oligonucleotide derived from ribosomal DNA. However, DNA denaturation reversed the DNA modifications. The homopolymeric oligonucleotide dG/dC was modified while neither the dI/dC nor the dA/dT oligonucleotides were, consistent with covalent attachment of ecteinascidin 743 to the exocyclic amino group at position 2 of guanine. Ecteinascidin 743 was then compared to another known DNA minor groove alkylating agent, anthramycin, which has also been shown to alkylate guanine N2. Footprinting analyses with DNase I and 1,10-phenanthroline-copper and exonuclease III digestions showed that ecteinascidin 743 covers three to five bases of DNA and exhibits a different sequence specificity than anthramycin in the Escherichia coli tyrosine tRNA promoter (tyrT DNA). The binding of ecteinascidin to DNA was abolished when guanines were substituted with inosines in this promoter. A band shift assay was designed to evaluate the influence of the bases flanking a centrally located guanine in an oligonucleotide containing inosines in place of guanines elsewhere. Ecteinascidin 743 and anthramycin showed similarities as well as differences in sequence selectivity. Ecteinascidin 743-guanine adducts appeared to require at least one flanking guanine and were strongest when the flanking guanine was 3' to the targeted guanine. These data indicate that ecteinascidin 743 is a novel DNA minor groove, guanine-specific alkylating agent.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8873596     DOI: 10.1021/bi960306b

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  71 in total

1.  Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove.

Authors:  Y Takebayashi; P Pourquier; A Yoshida; G Kohlhagen; Y Pommier
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-22       Impact factor: 11.205

2.  Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743.

Authors:  M Minuzzo; S Marchini; M Broggini; G Faircloth; M D'Incalci; R Mantovani
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

3.  Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors.

Authors:  Laura Vidal; Margarita Magem; Clare Barlow; Beatriz Pardo; Amalia Florez; Ana Montes; Margarita Garcia; Ian Judson; Claudia Lebedinsky; Stan B Kaye; Ramón Salazar
Journal:  Invest New Drugs       Date:  2010-10-07       Impact factor: 3.850

4.  Phase I combination study of trabectedin and capecitabine in patients with advanced malignancies.

Authors:  Lia Gore; E Rivera; M Basche; S L Moulder-Thompson; J Li; S Eppers; S Grolnic; C O'Bryant; D Cleere; Y A Elsayed; S G Eckhardt
Journal:  Invest New Drugs       Date:  2011-09-20       Impact factor: 3.850

5.  Trabectedin (ET-743, Yondelis) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype.

Authors:  Jan-Hendrik Beumer; Tessa Buckle; Mariet Ouwehand; Niels E F Franke; Luis Lopez-Lazaro; Jan H M Schellens; Jos H Beijnen; Olaf van Tellingen
Journal:  Invest New Drugs       Date:  2007-02       Impact factor: 3.850

6.  PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity.

Authors:  J F M Leal; M Martínez-Díez; V García-Hernández; V Moneo; A Domingo; J A Bueren-Calabuig; A Negri; F Gago; M J Guillén-Navarro; P Avilés; C Cuevas; L F García-Fernández; C M Galmarini
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

7.  Dynamics of cell cycle phase perturbations by trabectedin (ET-743) in nucleotide excision repair (NER)-deficient and NER-proficient cells, unravelled by a novel mathematical simulation approach.

Authors:  M Tavecchio; C Natoli; P Ubezio; E Erba; M D'Incalci
Journal:  Cell Prolif       Date:  2007-12       Impact factor: 6.831

8.  Disposition and toxicity of trabectedin (ET-743) in wild-type and mdr1 gene (P-gp) knock-out mice.

Authors:  J H Beumer; N E Franke; R Tolboom; T Buckle; H Rosing; L Lopez-Lazaro; J H M Schellens; J H Beijnen; O van Tellingen
Journal:  Invest New Drugs       Date:  2009-02-24       Impact factor: 3.850

9.  A phase I trial and pharmacokinetic study of a 24-hour infusion of trabectedin (Yondelis®, ET-743) in children and adolescents with relapsed or refractory solid tumors.

Authors:  Meredith K Chuk; Alberta Aikin; Trish Whitcomb; Brigitte C Widemann; Peter Zannikos; Eliel Bayever; Frank M Balis; Elizabeth Fox
Journal:  Pediatr Blood Cancer       Date:  2012-07-27       Impact factor: 3.167

10.  Identification of GAPDH as a protein target of the saframycin antiproliferative agents.

Authors:  Chengguo Xing; Jacob R LaPorte; Joseph K Barbay; Andrew G Myers
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.